Spinifex Pharmaceuticals makes two senior appointments in CMC team

Peter Spargo joins as SVP, CMC with Christine Richardson as Director, CMC and Nonclinical Project Manager

Australian biotech Spinifex Pharmaceuticals, a developer of drugs for the treatment of chronic pain, has enhanced its Chemistry, Manufacturing & Controls (CMC) capability as it continues to drive the development of its lead candidate, EMA401, in a number of chronic pain indications.

Peter Spargo has joined the company as Senior Vice President, CMC. He has been involved in pharmaceutical research and development throughout an international career spanning more than 25 years. He has previously acted as an industry consultant, including to Spinifex, and held the role of SVP CMC at Creabilis (Italy and UK) and at Novexel (France). At Novexel he played an important role in the company's US$500m acquisition by AstraZeneca in 2010.

His industry career began at Pfizer (Sandwich, UK) where his final position was as Head of Chemical R&D for Pfizer in Europe. He also led Pfizer Pharmaceutical Sciences development teams, embracing formulation and analytical activities, as well as chairing multi-disciplinary human health development teams and being responsible for the company's Worldwide Pharmaceutical Sciences Veterinary Medicines portfolio.

Christine Richardson has joined Spinifex as Director, CMC and Nonclinical Project Manager. Most recently Richardson was Global Program Operations Manager at Novartis Pharmaceuticals (East Hanover, NJ, US). Her pharmaceutical career began at Novartis in New York and she has held a number of positions with the company in the US and in Europe.

You may also like

Research & Development

Spinifex Pharmaceuticals sold to Novartis

Novartis will continue to develop the company’s programmes to address neuropathic pain
Regulatory

Neuropathic pain – EMA401

Pain that arises as a direct consequence of a lesion or disease affecting the somatosensory system is notoriously difficult to treat
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now